Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | L3MBTL3 | Q96JM7 | 12/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 11/20 | 0.44 |
| ▸ | MBTD1 | Q05BQ5 | 6/20 | 0.44 |
| ▸ | TP53BP1 | Q12888 | 3/20 | 0.43 |
| ▸ | L3MBTL4 | Q8NA19 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1711612 | 0.98 | MEN1 (0.43) | MEN1KMT2AL3MBTL3L3MBTL1MBTD1 | |
| SCHEMBL28452884 | 0.95 | L3MBTL3 (0.41) | MEN1KMT2AL3MBTL3L3MBTL1MBTD1 | |
| SCHEMBL1306958 | 0.86 | MEN1 (0.42) | MEN1KMT2AL3MBTL3L3MBTL1MBTD1 | |
| SCHEMBL28012195 | 0.85 | MEN1 (0.41) | MEN1KMT2AL3MBTL3L3MBTL1MBTD1 | |
| SCHEMBL5016034 | 0.84 | MEN1 (0.43) | MEN1KMT2AL3MBTL3L3MBTL1MBTD1 | |
| SCHEMBL3083396 | 0.81 | MEN1 (0.44) | MEN1KMT2AL3MBTL3L3MBTL1KDM4E | |
| SCHEMBL5429121 | 0.81 | MEN1 (0.41) | MEN1KMT2AKDM4E | |
| SCHEMBL24582089 | 0.80 | KMT2A (0.43) | MEN1KMT2AL3MBTL3L3MBTL1 | |
| SCHEMBL20649140 | 0.80 | KDM4E (0.45) | MEN1KMT2AKDM4ECYP2D6 | |
| SCHEMBL1306670 | 0.80 | L3MBTL1 (0.38) | MEN1KMT2AL3MBTL3L3MBTL1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 111 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3704102-B1 | SUBSTITUTED QUINOLINE ANALOGS AS ALDEHYDE DEHYDROGENASE 1A1 (ALDH1A1) INHIBITORS | US HEALTH (US) | 2024-02-28 | — | — | EP | claimed |
| WO-2024035194-A1 | NOVEL HETEROARYL-SUBSTITUTED DERIVATIVE AND COMPOSITION FOR PREVENTING OR TREATING NEURODEGENERATIVE DISEASE, CANCER, AND INFLAMMATORY DISEASE COMPRISING SAME | 환인제약 주식회사 | 2024-02-15 | — | — | WO | claimed |
| CN-111491918-B | Aryl and heteroaryl substituted indole compounds | 百时美施贵宝公司 | 2023-10-24 | — | — | CN | claimed |
| US-20220388967-A1 | Phenyl Amino Pyrimidine Compounds and Uses Thereof | SIERRA ONCOLOGY, INC. (US) | 2022-12-08 | — | — | US | claimed |
| CN-115413278-A | Novel pyrimidine derivative and composition for preventing or treating neurodegenerative disease and cancer comprising same | 丸仁制药株式会社 | 2022-11-29 | — | — | CN | claimed |
| CN-111491918-A | Aryl and heteroaryl substituted indole compounds | 百时美施贵宝公司 | 2020-08-04 | — | — | CN | claimed |
| US-20200207779-A2 | THIENOPYRIMIDINE COMPOUND, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | Hongyun Biotech Co., Ltd. (CN) | 2020-07-02 | — | — | US | claimed |
| CN-106660955-B | Cyclohexene derivative, preparation method and the pharmaceutical composition for being used to prevent or treat metabolic disease comprising it as active constituent | 现代药品株式会社 | 2019-08-23 | — | — | CN | claimed |
| US-20190211030-A1 | THIENOPYRIMIDINE COMPOUND, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | Hongyun Biotech Co., Ltd. (CN) | 2019-07-11 | — | — | US | claimed |
| EP-3498716-A1 | THIENOPYRIMIDINE COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION, AND APPLICATIONS | Hongyun Biotech Co., Ltd. (CN) | 2019-06-19 | — | — | EP | claimed |
| CN-101272685-A | Diarylamine-containing compounds and compositions, and their use as modulators of C-KIT receptors | IRM LLC (BM) | 2008-09-24 | — | — | CN | claimed |
| WO-2008109943-A1 | PHENYL AMINO PYRIMIDINE COMPOUNDS AND USES THEREOF | CYTOPIA RESEARCH PTY LTD (AU) | 2008-09-18 | — | — | WO | claimed |
| WO-2007086080-A2 | NOVEL IMIDAZO[1,2-a]PYRIDINE CANNABINOID RECEPTOR LIGANDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | GLENMARK PHARMACEUTICALS LIMITED (IN) | 2007-08-02 | — | — | WO | claimed |
| EP-1268444-B1 | 2,4-DI(HETERO-)ARYLAMINO(-OXY)-5-SUBSTITUTED PYRMIDINES AS ANTINEOPLASTIC AGENTS | ASTRAZENECA AB (SE) | 2007-01-17 | — | — | EP | claimed |
| CN-1273469-C | Tricyclic diazepines as tocolytic oxytocin receptor antagonists | WYETH CORP (US) | 2006-09-06 | — | — | CN | claimed |
| US-6649608-B2 | Cyclin-dependent serine/threonine and focal adhesion kinase inhibitors | ASTRAZENECA AB (SE) | 2003-11-18 | — | — | US | claimed |
| JP-2003525278-A | — | — | 2003-08-26 | — | — | JP | claimed |
| US-20030149266-A1 | 2,4-Di(hetero-)arylamino (oxy)-5-substituted pyrimidines as antineoplastic agents | ASTRAZENECA AB (SE) | 2003-08-07 | — | — | US | claimed |
| EP-1268444-A1 | 2,4-DI(HETERO-)ARYLAMINO(-OXY)-5-SUBSTITUTED PYRMIDINES AS ANTINEOPLASTIC AGENTS | AstraZeneca AB (SE) | 2003-01-02 | — | — | EP | claimed |
| WO-2001064655-A1 | 2, 4-DI(HETERO-)ARYLAMINO (-OXY)-5-SUBSTITUTED PYRIMIDINES AS ANTINEOPLASTIC AGENTS | ASTRAZENECA AB (SE) | 2001-09-07 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030149266-A1 | 2,4-Di(hetero-)arylamino (oxy)-5-substituted pyrimidines as antineoplastic agents | CDK2, CCNI, CDK1 | MEN1 3568/4885KMT2A 680/4885L3MBTL3 3586/4885 |
| US-20190211030-A1 | THIENOPYRIMIDINE COMPOUND, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | ALK, MET, TIE1 | MEN1 931/4885KMT2A 883/4885L3MBTL3 1968/4885 |
| US-20220388967-A1 | Phenyl Amino Pyrimidine Compounds and Uses Thereof | JAK2, JAK1, JAK3 | MEN1 4037/4885KMT2A 835/4885L3MBTL3 2030/4885 |
| US-20200207779-A2 | THIENOPYRIMIDINE COMPOUND, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | ALK, MET, TIE1 | MEN1 931/4885KMT2A 883/4885L3MBTL3 1968/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.